Matrix metalloproteinase-1 peptide–HLA class I complex (MMP1–HLA-I complex)

The Matrix metalloproteinase-1 (MMP1) peptide–HLA class I complex is a specialized immunological target consisting of a degraded peptide fragment of the MMP1 enzyme bound within the groove of a Human Leukocyte Antigen (HLA) class I molecule. MMP1 is an interstitial collagenase often overexpressed in various solid tumors, where it facilitates extracellular matrix remodeling and promotes metastasis. When tumor cells process MMP1, specific peptides are presented on the cell surface via HLA molecules, most commonly HLA-A*02:01, making the complex a highly specific marker for malignant cells. This peptide-MHC (pMHC) complex is a primary target for cancer immunotherapies, including T-cell receptor (TCR) engineered T-cell therapies and therapeutic cancer vaccines. By targeting this complex, the immune system can be directed to selectively identify and eliminate cancer cells while potentially sparing normal tissues that do not present the antigen at the same density. However, therapeutic development must account for the physiological roles of MMP1 in wound healing and tissue repair to avoid off-target effects.

Other names

MMP1 peptide-MHC complexMMP-1 pMHCMatrix metalloproteinase-1–HLA-A*02:01 complexMMP1-derived peptide presented by HLA class I

The complex acts as a specific epitope recognized by the T-cell receptor (TCR) of CD8+ cytotoxic T lymphocytes. Therapeutic interventions, such as TCR-engineered T cells or peptide vaccines, aim to trigger an immune response where the T cells recognize this specific peptide-HLA complex on the surface of tumor cells, leading to targeted cell lysis and tumor destruction.